Rifaximin-containing in-situ gel for breast injection and preparation method of rifaximin-containing in-situ gel
The invention discloses rifaximin-containing in-situ gel for breast injection. The rifaximin-containing in-situ gel comprises the following components in percentage by mass: 0.1-15% of an active drug component existing in a dispersed way, 0.25-20% of an active drug component existing in an inclusion...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention discloses rifaximin-containing in-situ gel for breast injection. The rifaximin-containing in-situ gel comprises the following components in percentage by mass: 0.1-15% of an active drug component existing in a dispersed way, 0.25-20% of an active drug component existing in an inclusion compound form, 12-30% of poloxamer 407, 0.01-11% of poloxamer 188, 0.01-10% of a polymer drag reduction agent, 0.001-3% of a bacterial inhibitor, a pH regulator for regulating the pH value to 5.5-7.5 and the balance of injection water. The invention also discloses a preparation method of the rifaximin-containing in-situ gel for breast injection. Water is used as a solvent, so that the rifaximin-containing in-situ gel is good in biocompatibility, little in irritation and high in safety, exists in a liquid state under a storage condition, is completely formed within 4-15 seconds after being injected to the breast because of thermal stimulation inside the breast and can be used for effectively treating, preventing and controlling mastitis of milk cows within the whole dry cow period; and in addition, the sustained-release effect is remarkable, and the in-vitro drug release time is long and reaches up to 48 days. |
---|